TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07782970: A Randomized, Double-blind, Parallel Group Phase 3 Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) (PERSIST CRSwNP-1)

Sponsor: GlaxoSmithKline · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 218 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$565,728

Rescue Site Savings

+$377,152

Unlock Full NCT07782970 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07782970 Rescue Dossier →